209 related articles for article (PubMed ID: 35682838)
1. Prime Editing Permits the Introduction of Specific Mutations in the Gene Responsible for Duchenne Muscular Dystrophy.
Happi Mbakam C; Rousseau J; Tremblay G; Yameogo P; Tremblay JP
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682838
[TBL] [Abstract][Full Text] [Related]
2. Comparison of In-Frame Deletion, Homology-Directed Repair, and Prime Editing-Based Correction of Duchenne Muscular Dystrophy Mutations.
Zhao X; Qu K; Curci B; Yang H; Bolund L; Lin L; Luo Y
Biomolecules; 2023 May; 13(5):. PubMed ID: 37238739
[TBL] [Abstract][Full Text] [Related]
3. Gene editing of Duchenne muscular dystrophy using biomineralization-based spCas9 variant nanoparticles.
Li S; Du M; Deng J; Deng G; Li J; Song Z; Han H
Acta Biomater; 2022 Dec; 154():597-607. PubMed ID: 36243370
[TBL] [Abstract][Full Text] [Related]
4. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
Hanson B; Wood MJA; Roberts TC
RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
[TBL] [Abstract][Full Text] [Related]
5. Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy.
Young CS; Mokhonova E; Quinonez M; Pyle AD; Spencer MJ
J Neuromuscul Dis; 2017; 4(2):139-145. PubMed ID: 28505980
[TBL] [Abstract][Full Text] [Related]
6. Production of Duchenne muscular dystrophy cellular model using CRISPR-Cas9 exon deletion strategy.
Alizadeh F; Abraghan YJ; Farrokhi S; Yousefi Y; Mirahmadi Y; Eslahi A; Mojarrad M
Mol Cell Biochem; 2024 May; 479(5):1027-1040. PubMed ID: 37289342
[TBL] [Abstract][Full Text] [Related]
7. Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing.
Chemello F; Chai AC; Li H; Rodriguez-Caycedo C; Sanchez-Ortiz E; Atmanli A; Mireault AA; Liu N; Bassel-Duby R; Olson EN
Sci Adv; 2021 Apr; 7(18):. PubMed ID: 33931459
[TBL] [Abstract][Full Text] [Related]
8. CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy.
Happi Mbakam C; Lamothe G; Tremblay G; Tremblay JP
Neurotherapeutics; 2022 Apr; 19(3):931-941. PubMed ID: 35165856
[TBL] [Abstract][Full Text] [Related]
9. In vivo genome editing in mouse restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers.
Chen M; Shi H; Gou S; Wang X; Li L; Jin Q; Wu H; Zhang H; Li Y; Wang L; Li H; Lin J; Guo W; Jiang Z; Yang X; Xu A; Zhu Y; Zhang C; Lai L; Li X
Genome Med; 2021 Apr; 13(1):57. PubMed ID: 33845891
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas9-based genome editing for the modification of multiple duplications that cause Duchenne muscular dystrophy.
Wang DN; Wang ZQ; Jin M; Lin MT; Wang N
Gene Ther; 2022 Dec; 29(12):730-737. PubMed ID: 35534612
[TBL] [Abstract][Full Text] [Related]
11. CRISPR Therapeutics for Duchenne Muscular Dystrophy.
Erkut E; Yokota T
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163754
[TBL] [Abstract][Full Text] [Related]
12. Restoration of Dystrophin Protein Expression by Exon Skipping Utilizing CRISPR-Cas9 in Myoblasts Derived from DMD Patient iPS Cells.
Ifuku M; Iwabuchi KA; Tanaka M; Lung MSY; Hotta A
Methods Mol Biol; 2018; 1828():191-217. PubMed ID: 30171543
[TBL] [Abstract][Full Text] [Related]
13. A Novel CRISPR-Cas9 Strategy to Target DYSTROPHIN Mutations Downstream of Exon 44 in Patient-Specific DMD iPSCs.
Dhoke NR; Kim H; Azzag K; Crist SB; Kiley J; Perlingeiro RCR
Cells; 2024 Jun; 13(11):. PubMed ID: 38891104
[TBL] [Abstract][Full Text] [Related]
14. Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy.
Pickar-Oliver A; Gough V; Bohning JD; Liu S; Robinson-Hamm JN; Daniels H; Majoros WH; Devlin G; Asokan A; Gersbach CA
Mol Ther; 2021 Nov; 29(11):3243-3257. PubMed ID: 34509668
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9 editing of directly reprogrammed myogenic progenitors restores dystrophin expression in a mouse model of muscular dystrophy.
Domenig SA; Bundschuh N; Lenardič A; Ghosh A; Kim I; Qabrati X; D'Hulst G; Bar-Nur O
Stem Cell Reports; 2022 Feb; 17(2):321-336. PubMed ID: 34995499
[TBL] [Abstract][Full Text] [Related]
16. Restoration of dystrophin expression and correction of Duchenne muscular dystrophy by genome editing.
Aslesh T; Erkut E; Yokota T
Expert Opin Biol Ther; 2021 Aug; 21(8):1049-1061. PubMed ID: 33401973
[No Abstract] [Full Text] [Related]
17. New advancements in CRISPR based gene therapy of Duchenne muscular dystrophy.
Eslahi A; Alizadeh F; Avan A; Ferns GA; Moghbeli M; Reza Abbaszadegan M; Mojarrad M
Gene; 2023 May; 867():147358. PubMed ID: 36914142
[TBL] [Abstract][Full Text] [Related]
18. Prime editing optimized RTT permits the correction of the c.8713C>T mutation in
Happi Mbakam C; Rousseau J; Lu Y; Bigot A; Mamchaoui K; Mouly V; Tremblay JP
Mol Ther Nucleic Acids; 2022 Dec; 30():272-285. PubMed ID: 36320324
[TBL] [Abstract][Full Text] [Related]
19. Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy.
Bengtsson NE; Hall JK; Odom GL; Phelps MP; Andrus CR; Hawkins RD; Hauschka SD; Chamberlain JR; Chamberlain JS
Nat Commun; 2017 Feb; 8():14454. PubMed ID: 28195574
[TBL] [Abstract][Full Text] [Related]
20. CRISPR-Cas9 Correction of Duchenne Muscular Dystrophy in Mice by a Self-Complementary AAV Delivery System.
Zhang Y; Bassel-Duby R; Olson EN
Methods Mol Biol; 2023; 2587():411-425. PubMed ID: 36401041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
